Steba’s Tookad: US FDA Panel To Weigh Novel Endpoints, Missing Data And Toxicities

 
• By Sue Sutter
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra
Steba is seeking accelerated approval for low-risk, early-stage prostate cancer, but US FDA may want more data. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers